AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06303661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-intensity Shock Wave Therapy
Description: The equipment's applicator is covered with transparent PVC film and non-alcoholic gel is used as a coupling medium between the applicator and the penis. The following parameters are used: frequency of 10Hz, energy of 120mJ and 2,000 shots in the fibrotic plaque.
Study NCT03868943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soliramfetol
Description: Solriamfetol will be dosed by flexible dose titration starting at 75 mg daily in all patients and escalating after 7 days (1 week) to 150 mg daily and then after 7 days to 300 mg daily for a total duration of 3 weeks (flexible dose titration period).
Study NCT04955275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy Program (BrainHQ)
Description: Brain HQ games involving training cognitive abilities like memory and attention, made up of adapting tasks or creating our own.
Study NCT05107167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic stimulation
Description: Electromagnetic stimulation of the phrenic nerve
Study NCT04678648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RSC-1255 Dose Escalation
Description: Phase 1a will enroll 30-40 participants to identify the dose limiting toxicity (DLT), recommended Phase 1b dose, and the safety and tolerability of RSC-1255. RSC-1255 is administered orally twice daily, without food. Each cycle is 21 days.
Study NCT04678648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RSC-1255 Dose Expansion
Description: Phase 1b will enroll 48-104 participants to further characterize the safety, pharmacology, and clinical efficacy of RSC-1255. RSC-1255 is administered orally twice daily, without food. Each cycle is 21 days.
Study NCT05313867 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutri VX 1
Description: 1 sequence of 10 tablets (one intake)
Study NCT05313867 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 sequence of 10 tablets (one intake)
Study NCT05772845 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Acute (24-hour) abstinence
Description: Participants will be asked to abstain from all tobacco/nicotine for 24 hours prior to the visit
Study NCT05187273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Elastance Group
Description: Fluids are given based on dynamic elastane value
Study NCT06299488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sip2Sleep: Montmorency Cherry and Apocynum Venetum
Description: See arm description
Study NCT05277337 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alluzience
Description: Botulinum Toxin Type A (BoNT-A) for treatment of glabellar lines; Mode of administration: intramuscular injection
Study NCT05772845 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Ad libitum smoking/vaping
Description: Participants will be asked to smoke/vape as usual during the 24 hours prior to the visit
Study NCT06186687 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Myofunctional therapy exercise
Description: Myofunctional therapy involves various exercises to train muscles in the soft palate, tongue, face, and pharynx. Vocal letters are used to train the palatopharyngeus, palatoglossus, uvula, tensor veli palatine, and levator veli palatine muscles. Tongue exercises involve sliding the tongue to the upper and side surfaces of the teeth, placing the tip in front of the palate, and pressing and sucking the tongue up to the palate. Face exercises involve inflating the cheeks, gargling, and sucking the cheeks to exercise the orbicularis oris muscle and the buccinator muscle. Icing stimulates the mouth, producing a cold, chilling, and numbing effect, causing reflexive contraction of the palate, tongue, and pharyngeal muscles.
Study NCT05590598 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Azelastine + Mometazone, nasal spray
Description: 140 mcg + 50 mcg/dose (Sandoz d.d., Slovenia), one actuation in each nostril twice daily, morning and evening (recommended interval between administrations is approximately 12 hours), for 14 consecutive days.
Study NCT05590598 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Momat Rhino Advance
Description: 140 µg + 50 µg/dose - one actuation into each nostril twice daily - morning and evening (interval between administrations is 12 hrs), corresponding to 560 µg/day of azelastine and 200 µg/day of mometasone for 14 consecutive days
Study NCT05340205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: Patients will receive 1 gm tranexamic acid diluted in 20 ml of Glucose 5% 15 minutes prior to skin incision and a slow IV bolus of 5 IU oxytocin and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following delivery of the baby.
Study NCT05340205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Patients will receive 400 microgram misoprostol which will be inserted inside the uterus near the cornu after delivery of the placenta and a slow IV bolus of 5 IU oxytocin and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h).~.
Study NCT05340205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Patients will receive an IV bolus of 5 IU oxytocin and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following the delivery of the baby.
Study NCT05753826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: 20mg/kg，D1，q3W
Study NCT05753826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fuzuloparib
Description: 100 mg bid
Study NCT05674474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorasidenib
Description: Administered orally as tablets.
Study NCT02120755 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AmnioClear™ Human Allograft Amniotic Membrane
Study NCT05996796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colli-Pee Small Volumes
Description: Women will self-collect a first-void urine sample at home upon receipt of the study package using the Colli-Pee Small Volumes (10 mL) device (Novosanis, Belgium). The collector tube is prefilled with a preservative (UCM, Novosanis, Belgium). Women will send the collector vial containing first-void urine along with the informed consent form to the laboratory at University of Antwerp using the prestamped envelope.
Study NCT05996796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evalyn Brush
Description: Women will self-collect a vaginal sample at home upon receipt of the study package using the Evalyn Brush device (Rovers Medical Devices, The Netherlands). Women will send the used brush along with the informed consent form to the laboratory at University of Antwerp using the prestamped envelope.
Study NCT05079490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motor intervention
Description: gross motor skill intervention combined with fitness training
Study NCT01222650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSO-0400
Study NCT01222650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin
Study NCT01222650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04361201 — intervention group
Intervention type: PROCEDURE
Intervention: Ligament plastic surgery
Description: Ligament plastic surgery of ankle under arthroscopy for recurrent instable ankle reason and failure of medical treatment.
Study NCT04361201 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: RMI and ultrasound
Description: RMI examination at 3 months on operated ankle, and 3 CT scan examinations with elastography module will be performed at planned timeframes.
Study NCT05301075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhomboid Intercostal and Sub-Serratus block
Description: Rhomboid Intercostal and Sub-Serratus block under ultrasound guidance
Study NCT05301075 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Rhomboid Intercostal and Sub-Serratus block
Description: Rhomboid Intercostal and Sub-Serratus block under ultrasound guidance
Study NCT05728879 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: APR-TD011 (RLF-TD011)
Description: APR-TD011 (RLF-TD011) wound cleansing spray (drug/device combination product with a 510k clearance that is commercially marketed in the US for use by or on the order of a physician.
Study NCT03884400 — intervention group
Intervention type: PROCEDURE
Intervention: Specimens obtained from surgical, phlebotomy or other non-invasive procedure
Description: Biospecimen Collection
Study NCT05611957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC.
Study NCT04992143 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE first ,and more TACE could be performed when it is necessary.
Study NCT05636241 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy program
Description: The conventional physiotherapy program consists of stretching exercises for lower extremities, strength exercises for core, upper, and lower extremity muscles, sit to stand exercises, and balance exercises.
Study NCT05636241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body vibration training program
Description: The whole body vibration training program sessions consisted of three 3-min bouts of vibration of 20 Hz and a peak-to-peak amplitude of 2mm with a 3-min rest in between, in addition to conventional physiotherapy exercises for children with cerebral palsy.
Study NCT04992143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilelizumab
Description: Tilelizumab 240mg per 3weeks ivgtt within 1 week after the first TACE
Study NCT04992143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib should be administered 400 mg twice /day orally within 1 week after the first TACE
Study NCT05637554 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic appendectomy using clipping.
Description: Laparoscopic appendectomy using clipping to secure the base of the appendix.
Study NCT05037006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane - Neostigmine 30
Description: Neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOFc 3
Study NCT05637554 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic appendectomy using extracorporeal ligation to secure the base of the appendix.
Description: Laparoscopic appendectomy using extracorporeal ligation to secure the base of the appendix.
Study NCT04615637 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEG recordings
Description: 1. Classical MEG recordings (patient at rest, normal subjects stimulated with visual, motor, somesthesic and auditory stimuli).~2. MEG recordings with our OPM He4 prototype (patient at rest, normal subjects stimulated with visual, motor, somesthesic and auditory stimuli).
Study NCT05037006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane - Neostigmine 50
Description: Neostigmine 50 mcg/kg and atropine 25 mcg/kg when TOFc 3
Study NCT05037006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane - Neostigmine 70
Description: Neostigmine 70 mcg/kg and atropine 35 mcg/kg when TOFc 3
Study NCT05037006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIVA - Neostigmine 30
Description: Neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOFc 3
Study NCT05037006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIVA - Neostigmine 50
Description: Neostigmine 50 mcg/kg and atropine 25 mcg/kg when TOFc 3
Study NCT05037006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIVA - Neostigmine 70
Description: Neostigmine 70 mcg/kg and atropine 35 mcg/kg when TOFc 3
Study NCT05699005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Packed Red Blood Cells (PRBCs)
Description: Patient will recieve PRBCs transfusion only in case of ScVO2 level\<65% after assessment of patient for optimisation of SaO2 targeting 100%, volume status, ECMO flow (increase to 20% in relevant), pain, anxiety and fever (body temperature >38°3).~In both groups transfusion may be performed in case massive bleeding according to local protocols, STEMI, Hyperlactatemia >4 that can be related to oxygen demand and supply DO2/VO2 ratio impairement, in all groups, transfusion should be performed in case of hemolobin level \<7g/dL or worsening of neurological condition (Increase in Neurological SOFA component of 1 and more) related to DO2/VO2 impairement.
Study NCT05699005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Packed Red Blood Cells (PRBCs)
Description: Patient will recieve PRBCs transfusion only in case of ScVO2 level\<65% after assessment of patient for optimisation of SaO2 targeting 100%, volume status, ECMO flow (increase to 20% in relevant), pain, anxiety and fever (body temperature >38°3).~In both groups transfusion may be performed in case massive bleeding according to local protocols, STEMI, Hyperlactatemia >4 that can be related to oxygen demand and supply DO2/VO2 ratio impairement, in all groups, transfusion should be performed in case of hemolobin level \<7g/dL or worsening of neurological condition (Increase in Neurological SOFA component of 1 and more) related to DO2/VO2 impairement.
Study NCT05277337 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: powder BoNT-A (BOTOX/Vistabel)
Description: Botulinum Toxin Type A (BoNT-A) for treatment of glabellar lines; Mode of administration: intramuscular injection
Study NCT06158646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kinematic knee prosthesis
Description: Patients with a kinematically aligned total knee prosthesis and having a post-operative follow-up consultation within at least 1 year after their surgery are consecutively pre-selected according to the eligibility criteria.
Study NCT06158646 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: biomechanic knee prosthesis
Description: A group of patients with a mechanically aligned TKA and scheduled for a follow-up consultation 1 year after surgery will be identified to be matched on the aforementioned criteria (sex, age, BMI).
Study NCT05091320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical thrombectomy
Description: Mechanical thrombectomy is interventional method and the first line management in large vessel occlusion in acute ischemic stroke
Study NCT05091320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medical treatment
Description: medical management of patient according guide lines, either alteplase if presented in it's time window, or anti-platelet
Study NCT05049603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg
Description: One tablet/day, given approximately at 10 pm, after dinner and before going to bed, for 24 weeks
Study NCT05049603 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet/day, given approximately at 10 pm, after dinner and before going to bed, for 24 weeks
Study NCT05429567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: All patients underwent combined spinal and epidural anesthesia (CSEA) with 2 ml of 0.5 % hyperbaric bupivacaine and 25 ug fentanyl administered using a 27-gauge Whitacre spinal needle and an 18-gauge Tuohy needle in the epidural space. The epidural space was identified utilizing the loss of resistance approach
Study NCT05347641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab
Description: Penpulimab + RMA regimen:~Rituximab 375 mg/m2 d0 iv Methotrexate (MTX) 3.5g/m2 drip D1 Cytarabine \* (ARA-C) 1-2g/m2 q12H D2-3 iv Penpulimab 200 mg iv D5
Study NCT04336930 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pupillary pain index (PPI)
Description: Measurement of PPI with a pupillometer
Study NCT05606133 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NavDx(R)
Description: NavDx® is a blood test that utilizes digital droplet PCR in order to quantify fragments of tumor-specific DNA shed by HPV-associated cancer cells in the blood. The technology has the ability to distinguish tumor-tissue modified virus particles present in the plasma cell-free DNA from non-cancer associated sources of HPV DNA.
Study NCT04957186 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collection of postoperative information
Description: The EORTC BR45 questionnaire will be used to gather information from patients regarding possible post-operative complications recorded via electronic patient-reported outcomes (pain, swelling, hypersensitivity etc.) as well as via the interviews with the state-registered coordinating nurse.
Study NCT04957186 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Analysis of postoperative information collected from patients
Description: All post-operative complications recorded via electronic patient-reported outcomes (pain, swelling, hypersensitivity etc.) as well as via the interviews with the state-registered coordinating nurse will be analyzed with the aim of proposing an appropriate care pathway.
Study NCT06420310 — intervention group
Intervention type: OTHER
Intervention: exposure to pesticides
Description: based on work exposures to pesticides
Study NCT06028633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: pembrolizumab 200mg IV on day 1 for every 3 weeks
Study NCT06028633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: lenvatinib 8mg taken orally every day
Study NCT06028633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin-bound paclitaxel
Description: albumin-bound paclitaxel IV 100mg/m2 D1, 8 every 3 weeks
Study NCT05313542 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Physical Activity in the format of Self-defence Training
Study NCT05313542 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical Activity
Description: Physical Activity in the format of Self-defence Training
Study NCT05624333 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vegan diet (intervention)
Description: The intervention diet will be a fully controlled vegan diet that will be consumed for a duration of 10 days. No animal-based food products will be included in the diet.
Study NCT05606926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy program
Description: Flexibility exercises to restore joint mobility of soft tissues, Static and dynamic balance exercises, Functional gait training , Functional strengthening exercises will be conducted three times a week, for three consecutive months.
Study NCT05606926 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: physical therapy program
Description: Flexibility exercises to restore joint mobility of soft tissues, Static and dynamic balance exercises, Functional gait training , Functional strengthening exercises will be conducted three times a week, for three consecutive months.
Study NCT05606926 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: whole body vibration (without extra weight vest)
Description: 9 minutes of three sets of 3-min semi-squats on the vibration platform. three times a week, for three consecutive months.
Study NCT05606926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body vibration (with weight vest)
Description: The extra-weight applied in the vest will be calculated as 10% of the child body weight. The vest is designed to allow small bags of sand with different weights that are distributed equally on anterior-posterior and mediolateral plans.
Study NCT05624333 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Omnivorous diet (control)
Description: The control diet will be an a priori composed controlled omnivorous diet with a duration of 10 days. The omnivorous diet and the vegan diet will be isocaloric and isonitrogenous.
Study NCT05423405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: selected acupoint pressure
Study NCT05423405 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Acupressure
Description: selected acupoint pressure
Study NCT05489445 — intervention group
Intervention type: DEVICE
Intervention: KODEX - EPD
Description: A patient that is already clinically indicated to undergo cryoballoon ablation for atrial fibillation will use the The KODEX - EPD™ Cardiac Imaging and Navigation electrophysiological (EP) System. This is an imaging system which allows the physician real-time visualization of the catheters in a patients heart during the procedure, as well as display of cardiac images of the patients heart in a number of different formats. The KODEX - EPD system used in this study is cleared for commercial use by the FDA and therefore, it's use in this study constitutes as standard clinical use.
Study NCT04792710 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metronidazole
Description: Metronidazole 500 mg intravenous stat dose prior to skin incision
Study NCT04792710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole 500 mg intravenous stat dose prior to skin incision